Future longitudinal studies should include: (1) extended follow-up of existing trial cohorts (5–10 years) to assess sustained lipid-lowering effects and long-term safety; (2) real-world evidence analyses using national health databases to evaluate cardiovascular event prevention (e.g., stroke, myocardial infarction); and (3) cost-effectiveness studies comparing tafolecimab with other PCSK9 inhibitors over extended periods. The gene discussed is PCSK9; the disease is stroke disorder.